MedTrace Logo

Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results

NCT06459583 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 681

Last updated 2026-01-14

No results posted yet for this study

Summary

This randomized non-inferiority study will evaluate self-directed scalable electronic health platform (eHealth) methods for communicating Alzheimer's gene and biomarker results compared to videoconference telehealth disclosure with healthcare providers, as well as characterize the impacts of learning this information on the participant.

Conditions

  • Alzheimer Disease

Interventions

OTHER

eHealth Platform

The eHealth Platform consists of the ADWebPortal and ADChatbot for receiving Alzheimer's-related test results

OTHER

Videoconference Telehealth Platform

Participants will have a video telehealth visit with a healthcare provider to receive Alzheimer's-related test results

Sponsors & Collaborators

Principal Investigators

  • Jessica Langbaum, PhD · Banner Alzheimer's Institute

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-10
Primary Completion
2025-11-07
Completion
2025-11-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06459583 on ClinicalTrials.gov